Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb)
Bevacizumab（Arketin）, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), specifi_x005fcally binds to VEGF to prevent VEGF from binding to its receptor, thereby reducing neovascularization, inducing degeneration of existing blood vessels and inhibiting tumor growth. As a broad-spectrum anti-tumor agent, bevacizumab is a standard regimen recommended in treatment guidelines for various malig_x0002_nancies worldwide. Since entering the market, its efficacy and safety have been widely demonstrated in clinical practice.
Metastatic colorectal cancer; advanced, metastatic, or recurrent non-small cell lung cancer; recurrent glioblastoma; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer.